Journal article

Stage managing bipolar disorder

Michael Berk, Lesley Berk, Seetal Dodd, Sue Cotton, Craig Macneil, Rothanthi Daglas, Philippe Conus, Andreas Bechdolf, Steven Moylan, Gin S Malhi

Bipolar Disorders | WILEY | Published : 2014

Abstract

OBJECTIVES: Clinical staging is widespread in medicine - it informs prognosis, clinical course, and treatment, and assists individualized care. Staging places an individual on a probabilistic continuum of increasing potential disease severity, ranging from clinically at-risk or latency stage through first threshold episode of illness or recurrence, and, finally, to late or end-stage disease. The aim of the present paper was to examine and update the evidence regarding staging in bipolar disorder, and how this might inform targeted and individualized intervention approaches. METHODS: We provide a narrative review of the relevant information. RESULTS: In bipolar disorder, the validity of stagi..

View full abstract

Grants

Awarded by NATIONAL INSTITUTE OF MENTAL HEALTH


Funding Acknowledgements

MB has received grant/research support from the National Institute of Health, Cooperative Research Centre, Simons Autism Foundation, Cancer Council of Victoria, Stanley Medical Research Foundation, MBF, NHMRC, Beyond Blue, Geelong Medical Research Foundation, Bristol-Myers Squibb, Eli Lilly & Co., GlaxoSmithKline, Organon, Novartis, Mayne Pharma, and Servier; has served as a speaker for AstraZeneca, Bristol-Myers Squibb, Eli Lilly & Co., GlaxoSmithKline, Janssen Cilag, Lundbeck, Merck, Pfizer, Sanofi Synthelabo, Servier, Solvay, and Wyeth; and has served as a consultant to AstraZeneca, Bristol-Myers Squibb, Eli Lilly & Co., GlaxoSmithKline, Janssen Cilag, Lundbeck, and Servier. SD has received grant/research support from the Stanley Medical Research Institute, NHMRC, Beyond Blue, ARHRF, Simons Foundation, Geelong Medical Research Foundation, Eli Lilly & Co., GlaxoSmithKline, Organon, Mayne Pharma, and Servier; and has received speakers and advisory board fees from Eli Lilly & Co, and conference travel support from Servier. AB has received research support from the German Research Foundation (DFG), NARSAD, the German Ministry of Education and Research (BMBF), and the Faculty of Medicine of the University of Cologne, and for an investigator-initiated trial from Bristol-Myers Squibb; and has received speaker fees and travel support from Bristol-Myers Squibb, Eli Lilly & Co., Janssen Cilag, and Servier. SM has received grant/research support from Pfizer. GSM has received research support from AstraZeneca, Eli Lilly & Co., Organon, Pfizer, Servier and Wyeth; has served as a speaker for AstraZeneca, Eli Lilly & Co., Janssen-Cilag, Lundbeck, Pfizer, Ranbaxy, Servier, and Wyeth; and has been a consultant for AstraZeneca, Eli Lilly & Co., Janssen-Cilag, Lundbeck, and, Servier. LB, SC, CM, RD, and PC have no conflicts of interest to report.